Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Jan 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well an artificial intelligence system called ADBoard can help doctors make treatment recommendations for patients with liver and bile duct tumors, such as hepatocellular carcinoma and gallbladder cancer. The study will compare the suggestions made by ADBoard during tumor conferences to those made by doctors to see if ADBoard can provide similar recommendations, consider more patient information, and speed up the time it takes for patients to start their treatment after being discussed.

To participate in this study, you need to be at least 18 years old and diagnosed with specific types of liver or bile duct cancers. You also need to provide consent to join the trial and have your medical information available from the hospital. If you decide to participate, your treatment plan will be determined either with the help of ADBoard or without it. This study is not yet recruiting participants, but it aims to improve how quickly and effectively patients receive care for their conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Valid informed consent
• • Patient information available in the hospital information system or Health Data Platform (HDP)
• • Enrollment in the hepatobiliary tumor conference
• • Diagnosis of any of the following entities: Colorectal liver metastasis, Gallbladder carcinoma, Hepatocellular carcinoma (HCC), mixed cell carcinoma, or fibrolamellar carcinoma, Perihilar cholangiocarcinoma (Klatskin tumors), Intrahepatic cholangiocarcinoma (iCC)
• Exclusion Criteria:
• • Patient does not consent / incapable of giving consent
• • Missing findings in the hospital information system
• • Patient is seeking for a second opinion and is not being treated at the study institution